S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

Tyme Technologies Stock Forecast, Price & News

+0.03 (+2.86 %)
(As of 09/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.10 million shs
Average Volume7.09 million shs
Market Capitalization$185.98 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter.

Tyme Technologies logo

About Tyme Technologies

Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.38 out of 5 stars

Medical Sector

1088th out of 1,351 stocks

Pharmaceutical Preparations Industry

529th out of 664 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

What stocks does MarketBeat like better than Tyme Technologies?

Wall Street analysts have given Tyme Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tyme Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tyme Technologies?

Tyme Technologies saw a decline in short interest in August. As of August 13th, there was short interest totaling 3,340,000 shares, a decline of 31.7% from the July 29th total of 4,890,000 shares. Based on an average daily volume of 7,470,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 2.9% of the shares of the stock are sold short.
View Tyme Technologies' Short Interest

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Tyme Technologies

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) announced its quarterly earnings results on Tuesday, August, 10th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01.
View Tyme Technologies' earnings history

How has Tyme Technologies' stock price been impacted by COVID-19 (Coronavirus)?

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TYME shares have increased by 2.9% and is now trading at $1.08.
View which stocks have been most impacted by COVID-19

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the following people:
  • Steve Hoffman, Chairman & Chief Science Officer (LinkedIn Profile)
  • Richard Anthony Cunningham, Chief Executive Officer & Director
  • Frank L. Porfido, Chief Financial Officer
  • Jan M. van Tornout, Chief Medical Officer
  • Jonathan M. Eckard, Chief Business Officer

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Who are Tyme Technologies' major shareholders?

Tyme Technologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.81%), Millennium Management LLC (1.23%), BlackRock Inc. (1.11%), Geode Capital Management LLC (0.48%), State Street Corp (0.23%) and Ergoteles LLC (0.18%). Company insiders that own Tyme Technologies stock include David Carberry, Diana F Cantor, Douglas A Michels, James Biehl, Michael Demurjian, Steve Hoffman and Tornout Jan M Van.
View institutional ownership trends for Tyme Technologies

Which major investors are selling Tyme Technologies stock?

TYME stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Vanguard Group Inc., Charles Schwab Investment Management Inc., Susquehanna International Group LLP, and Bank of New York Mellon Corp. Company insiders that have sold Tyme Technologies company stock in the last year include Diana F Cantor, Michael Demurjian, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies
or view top insider-selling stocks.

Which major investors are buying Tyme Technologies stock?

TYME stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Ergoteles LLC, Qube Research & Technologies Ltd, Pathstone Family Office LLC, Pathstone Family Office LLC, Simplex Trading LLC, Boothbay Fund Management LLC, and LMR Partners LLP. Company insiders that have bought Tyme Technologies stock in the last two years include David Carberry, Douglas A Michels, James Biehl, Michael Demurjian, Steve Hoffman, and Tornout Jan M Van.
View insider buying and selling activity for Tyme Technologies
or or view top insider-buying stocks.

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $1.08.

How much money does Tyme Technologies make?

Tyme Technologies has a market capitalization of $185.98 million.

How many employees does Tyme Technologies have?

Tyme Technologies employs 18 workers across the globe.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is www.tymeinc.com.

Where are Tyme Technologies' headquarters?

Tyme Technologies is headquartered at 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at (212) 461-2315 or via email at [email protected].

This page was last updated on 9/25/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.